Gene · 2348
Papers3,253
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 3,253
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| European Society for Medical Oncology Gynaecological Cancers Congress 2026: key scientific advances from the oral sessions. | Int J Gynecol Cancer | 2026 | 42624675 | PubTator, text mining | PubMed |
| Phospholipid-modified glycogen nanoparticles for synergistic chemo-photothermal treatment of glioblastoma. | Nanoscale | 2026 | 42605539 | PubTator, text mining | PubMed |
| Concordance of folate receptor expression in ovarian cancer over time: A single-institution retrospective study. | Gynecol Oncol Rep | 2026 | 42598557 | PubTator, text mining | PubMed |
| Specificity of the Interactions of Folate-Based Vectors with Folate Receptor-α. | J Phys Chem B | 2026 | 42593133 | PubTator, text mining | PubMed |
| Therapeutic targeting of folate receptor alpha (FRα) by antibody-polymer-drug conjugate in testicular germ cell tumors. | Biomed Pharmacother | 2026 | 42570634 | PubTator, text mining | PubMed |
Integrated expression profiling of trophoblast cell-surface antigen 2 (TROP2), folate receptor alpha (FRα), and human epidermal growth factor receptor 2 (HER2) in endometrial Cancer across molecular classes, genomic alterations, and histologic subtypes. | Gynecol Oncol | 2026 | 42567118 | PubTator, text mining | PubMed |
| Folate Receptor Alpha (FRα/FOLR1) Immunohistochemical Expression Across Molecularly Classified Endometrial Carcinomas. | Int J Gynecol Pathol | 2026 | 42565327 | PubTator, text mining | PubMed |
| Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors. | Drug Deliv | 2026 | 42557654 | PubTator, text mining | PubMed |
| Remarkable Clinical Improvement after Folinic Acid Supplementation in Cerebral Folate Transport Deficiency and Epileptic Encephalopathy: A Case Report. | Mol Syndromol | 2026 | 42553823 | PubTator, text mining | PubMed |
| Folate Receptor Immunohistochemical Staining Heterogeneity in Gynecologic Cancers. | Int J Gynecol Pathol | 2026 | 42550590 | PubTator, text mining | PubMed |
| Association between HER2 expression, genomic characteristics, and tumor immune microenvironment dynamics in epithelial ovarian cancer. | Front Oncol | 2026 | 42548619 | PubTator, text mining | PubMed |
| HopeFOL, or FOL of problems? Leucovorin for autistic symptoms. | Oncologist | 2026 | 42536436 | PubTator, text mining | PubMed |
| Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges. | EClinicalMedicine | 2026 | 42534594 | PubTator, text mining | PubMed |
| Mirvetuximab Soravtansine and its TreatmentAssociated Ocular Adverse Effects. A Review of the Current Knowledge. | Cesk Slov Oftalmol | 2026 | 42531095 | PubTator, text mining | PubMed |
| Immunotherapy and Relevant Antibody-Drug Conjugates in Gynecologic Oncology: Recent Advances, Ongoing Challenges, and Future Directions. | Cancers (Basel) | 2026 | 42512405 | PubTator, text mining | PubMed |
| Integrated Serum Multiomics Reveal Subtype-Specific Immune Dysregulation and Sex-Dimorphic Pathophysiology in Moyamoya Disease. | J Am Heart Assoc | 2026 | 42500892 | PubTator, text mining | PubMed |
| Case Report: Durable response to mirvetuximab soravtansine in a patient with platinum-sensitive ovarian cancer and a diagnosis of myelodysplastic syndrome. | Front Oncol | 2026 | 42494605 | PubTator, text mining | PubMed |
| Rapidly Progressing Bilateral Cataracts during Mirvetuximab Soravtansine Therapy: A Case Series. | Ocul Oncol Pathol | 2026 | 42483486 | PubTator, text mining | PubMed |
| Treatment Sequencing in Platinum-Resistant Epithelial Ovarian Cancer After MIRASOL, KEYNOTE-B96, and ROSELLA. | Int J Womens Health | 2026 | 42453787 | PubTator, text mining | PubMed |
| Mirvetuximab Soravtansine in the Treatment of Chemotherapy-Resistant Ovarian Cancer: A Systematic Review. | Int J Mol Sci | 2026 | 42450158 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2348/papers?page=2